keyword
MENU ▼
Read by QxMD icon Read
search

zoledronic

keyword
https://www.readbyqxmd.com/read/29043461/effect-of-anti-angiogenesis-induced-by-chemotherapeutic-monotherapy-chemotherapeutic-bisphosphonate-combination-therapy-and-anti-vegfa-mab-therapy-on-tooth-extraction-socket-healing-in-mice
#1
Yuri Akita, Shinichiro Kuroshima, Kazunori Nakajima, Hiroki Hayano, Riho Kanai, Muneteru Sasaki, Takashi Sawase
Osteonecrosis of the jaw (ONJ), which is a rare but severe adverse effect, mainly occurs in oncology patients receiving chemotherapeutic agents and bisphosphonates. However, the combined impact of chemotherapy and bisphosphonates on wound healing after tooth extraction remains unknown. The aim of this study was to determine the precise etiology of ONJ induced by chemotherapy and bisphosphonate combination therapy. Mice received zoledronate (ZA) monotherapy, cyclophosphamide (CY) monotherapy or CY/ZA combination therapy...
October 17, 2017: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29042034/evaluation-of-mandibular-fracture-healing-in-rats-under-zoledronate-therapy-a-histologic-study
#2
Mohammad Zandi, Arash Dehghan, Payam Amini, Leila Rezaeian, Shideh Doulati
INTRODUCTION: To evaluate fracture healing in mandible of rats under zoledronate therapy. METHODS: A total of 135 Wistar rats were randomly allocated into 3 groups. Group L received two intravenous infusion of 0.06 mg/kg zoledronate 6 weeks apart. Group H received the same dose of zoledronate as group L once a week for 6 weeks and group C were treated with normal saline. Seven days after the last infusion, rats underwent unilateral mandibular osteotomy to replicate a fracture...
October 14, 2017: Injury
https://www.readbyqxmd.com/read/29037985/adjuvant-zoledronic-acid-to-treat-breast-cancer-not-for-all
#3
Luís Costa, Arlindo R Ferreira
No abstract text is available yet for this article.
October 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29037984/effect-of-maf-amplification-on-treatment-outcomes-with-adjuvant-zoledronic-acid-in-early-breast-cancer-a-secondary-analysis-of-the-international-open-label-randomised-controlled-phase-3-azure-big-01-04-trial
#4
Robert Coleman, Andrew Hall, Joan Albanell, Andrew Hanby, Richard Bell, David Cameron, David Dodwell, Helen Marshall, Joël Jean-Mairet, Juan-Carlos Tercero, Federico Rojo, Walter Gregory, Roger R Gomis
BACKGROUND: Adjuvant use of bisphosphonates can reduce the incidence of bone metastases in early breast cancer. Recurrence and survival seem to be improved only in postmenopausal patients, but the underlying mechanisms remain unclear. We investigated whether MAF amplification (a biomarker for bone metastasis) in primary tumours could predict the treatment outcomes of adjuvant zoledronic acid. METHODS: The study population included patients enrolled in the international, open-label, randomised, controlled, phase 3 AZURE trial at eligible UK sites who had stage II or III breast cancer and who gave consent for use of their primary tumour samples...
October 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29035643/role-of-bone-modifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update
#5
Catherine Van Poznak, Mark R Somerfield, William E Barlow, J Sybil Biermann, Linda D Bosserman, Mark J Clemons, Sukhbinder K Dhesy-Thind, Melissa S Dillmon, Andrea Eisen, Elizabeth S Frank, Reshma Jagsi, Rachel Jimenez, Richard L Theriault, Theodore A Vandenberg, Gary C Yee, Beverly Moy
Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases...
October 16, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29035507/sequential-delivery-of-doxorubicin-and-zoledronic-acid-to-breast-cancer-cells-by-cb-7-modified-iron-oxide-nanoparticles
#6
Farah Benyettou, Marwa Alhashimi, Matthew O'Connor, Renu Pasricha, Jérémy Brandel, Hassan Trabousli, Javed Mazher, John-Carl Olsen, Ali Trabolsi
Drug-loaded magnetic nanoparticles were synthesized and used for the sequential delivery of the anti-resorptive agent zoledronic acid (Zol) and the cytotoxic drug doxorubicin (Dox) to breast cancer cells (MCF-7). Zol was attached to bare iron oxide nanoparticles (IONPs) via phosphonate coordination to form Z-NPs. The unbound imidazole of Zol was then used to complex the organic macrocycle CB[7] to obtain CZ-NPs. Dox was then complexed to the CZ-NPs to form the fully loaded particles (DCZ-NPs), which were stable in solution at 37 ºC and physiological pH (7...
October 16, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29033761/drug-induced-autoimmune-hepatitis-following-treatment-with-zoledronic-acid
#7
Jenny Sarah Schneider, Matteo Montani, Felix Stickel
Adverse drug reactions are among the most frequent side effects of synthetic and complementary alternative drugs and represent the premier causes of license revocations and acute liver failure. Drug-induced liver injury can resemble literally any other genuine liver disease and usually responds well to drug dechallenge. However, in some cases autoimmune-like hepatitis can evolve, requiring short- and sometimes long-term immunosuppression. Here, we present the hitherto first case of autoimmune-like hepatitis following treatment with zoledronic acid...
May 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29033381/the-effect-of-once-yearly-zoledronic-acid-on-hip-structural-and-biomechanical-properties-derived-using-computed-tomography-ct-in-japanese-women-with-osteoporosis
#8
Masako Ito, Teruki Sone, Masataka Shiraki, Satoshi Tanaka, Chika Irie, Yuri Ota, Toshitaka Nakamura
The effects of zoledronic acid on hip structural and biomechanical properties were evaluated in Japanese patients with osteoporosis by computed tomography (CT). The subjects included in this study were a subset of female subjects (zoledronic acid group, 49 subjects; placebo group, 53 subjects) in the phase 3 trial (ZONE study) who were available for multi-detector row CT (MDCT) scanning. Eligible subjects were those diagnosed with primary osteoporosis based on the Diagnostic Criteria for Primary Osteoporosis (2000) by the Japanese Society for Bone and Mineral Research and who had between one and four fractured vertebrae located between the fourth thoracic vertebra and the fourth lumbar vertebra...
October 12, 2017: Bone
https://www.readbyqxmd.com/read/29026845/osteonecrosis-of-the-jaws-in-patient-received-bisphosphonates-and-sunitinib-separately-a-case-report
#9
Farzaneh Ashrafi, Ali Derakhshandeh, Bijan Movahedian, Azadeh Moghaddas
Recently published reports have suggested that antiangiogenic drugs such as sunitinib could potentiate the osteonecrosis of the jaw (ONJ) induced by bisphosphonates (BPs) and even induce this adverse effect per se. We reported a case of ONJ with renal cell carcinoma under sunitinib medication and history of BPs therapy. A 53-year-old man was referred to the oral surgery clinic complaining of painful exposed oral lesion and bone extraction from right lower jaw in the mouth. He underwent nephrectomy followed by 5 months treatment with cycles of 50 mg sunitinib (Sutent(®)) once a day for 4 weeks followed by 2 weeks drug free before lesion exposure in October 2016...
July 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/29025652/high-activity-chitosan-nano-hydroxyapatite-zoledronic-acid-scaffolds-for-simultaneous-tumor-inhibition-bone-repair-and-infection-eradication
#10
Yao Lu, Mei Li, Lihua Li, Shuzhen Wei, Xiaoming Hu, Xiaolan Wang, Guiqiu Shan, Yu Zhang, Hong Xia, Qingshui Yin
Implanted biomaterials combined tumor inhibition and bone repair property are urgently needed to address the huge bone destruction and the high local recurrence following primary surgery in bone tumor therapy. In this work, a high-activity chitosan/nano hydroxyapatite (CS/nHA) scaffold containing zoledronic acid (CS/nHA/Zol) was prepared with a facile method. The prepared CS/nHA/Zol scaffolds exhibited excellent tumor inhibition property towards giant cell tumor of bone (GCT) in vitro through inducing cells apoptosis by up-regulating pro-apoptosis genes expression and reducing the osteoclastic activity of tumor cells by down-regulating osteoclastic genes...
January 1, 2018: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/29023215/cost-effectiveness-analysis-of-monthly-zoledronic-acid-zoledronic-acid-every-3-months-and-monthly-denosumab-in-women-with-breast-cancer-and-skeletal-metastases-calgb-70604-alliance
#11
Charles L Shapiro, James P Moriarty, Stacie Dusetzina, Andrew L Himelstein, Jared C Foster, Stephen S Grubbs, Paul J Novotny, Bijan J Borah
Purpose Skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, or the necessity for radiation or surgery to bone metastasis cause considerable morbidity, decrements in quality of life, and costs to the health care system. The results of a recent large randomized trial (Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs. We sought to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases...
October 12, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29018937/local-effect-of-zoledronic-acid-on-new-bone-formation-in-posterolateral-spinal-fusion-with-demineralized-bone-matrix-in-a-murine-model
#12
Pawel Zwolak, Jan Farei-Campagna, Thorsten Jentzsch, Brigitte von Rechenberg, Clément M Werner
BACKGROUND: Posterolateral spinal fusion is a common orthopaedic surgery performed to treat degenerative and traumatic deformities of the spinal column. In posteriolateral spinal fusion, different osteoinductive demineralized bone matrix products have been previously investigated. We evaluated the effect of locally applied zoledronic acid in combination with commercially available demineralized bone matrix putty on new bone formation in posterolateral spinal fusion in a murine in vivo model...
October 10, 2017: Archives of Orthopaedic and Trauma Surgery
https://www.readbyqxmd.com/read/28988216/efficacy-and-treatment-costs-of-zoledronate-versus-pamidronate-in-paediatric-osteoporosis
#13
Vrinda Saraff, Jaskiran Sahota, Nicola Crabtree, Sophia Sakka, Nicholas J Shaw, Wolfgang Högler
Intravenous pamidronate has been used in the treatment of osteogenesis imperfecta (OI) in children for over 20 years. The more potent zoledronate is an attractive alternative as it is administered less frequently. This study compares the clinical efficacy of intravenous pamidronate (1.5 mg/kg/day over 2 days, every 3 months) versus zoledronate (0.05 mg/kg/dose every 6 months) in 40 children (20 per group) with mild to moderate OI and the treatment costs of the two drugs in a tertiary centre for children with osteoporosis...
October 7, 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28983908/interventions-for-managing-medication-related-osteonecrosis-of-the-jaw
#14
REVIEW
Natalie H Beth-Tasdogan, Benjamin Mayer, Heba Hussein, Oliver Zolk
BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents) and involves the progressive destruction of bone in the mandible or maxilla. Depending on the drug, its dosage, and the duration of exposure, the occurrence of this adverse drug reaction may be rare (e.g. following the oral administration of bisphosphonate or denosumab treatments for osteoporosis, or antiangiogenic agent-targeted cancer treatment) or common (e...
October 6, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28978165/comparative-efficacy-and-safety-of-bone-modifying-agents-for-the-treatment-of-bone-metastases-in-patients-with-advanced-renal-cell-carcinoma-a-systematic-review-and-meta-analysis
#15
Kenji Omae, Yasushi Tsujimoto, Michitaka Honda, Tsunenori Kondo, Kazunari Tanabe, Shunichi Fukuhara, Toshi A Furukawa
OBJECTIVE: To determine the comparative efficacy and safety of all available bone-modifying agents (BMAs) for the treatment of bone metastases in patients with advanced renal cell carcinoma (RCC). RESULTS: Three studies (259 patients) were identified for the systematic review. Two studies that compared zoledronic acid with placebo or no zoledronic acid showed that zoledronic acid reduced the risk of skeletal-related events (SREs) by 68% (pooled hazard ratio [HR]: 0...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977163/use-of-cinacalcet-and-sunitinib-to-treat-hypercalcaemia-due-to-a-pancreatic-neuroendocrine-tumor
#16
Hernan Valdes-Socin, Matilde Rubio Almanza, Mariana Tomé Fernández-Ladreda, Daniel Van Daele, Marc Polus, Marcela Chavez, Albert Beckers
Neuroendocrine tumors (NETs) can secrete hormones, including ectopic secretions, but they have been rarely associated with malignant hypercalcemia. A 52-year-old man with a history of diabetes mellitus was diagnosed with a pancreatic tumor. A pancreatic biopsy confirmed a well-differentiated pancreatic NET (pNET). The patient subsequently developed liver metastasis and hypercalcemia with high 1,25 OH vitamin D and suppressed parathyroid hormone (PTH) levels. Hypercalcemia was refractory to chemotherapy, intravenous saline fluids, diuretics, calcitonin and zoledronate...
September 18, 2017: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28976594/healing-in-peri-implant-gap-with-bmp-2-and-systemic-bisphosphonate-is-dependent-on-bmp-2-dose-a-canine-study
#17
Rasmus Cleemann, Mette Sørensen, Joan E Bechtold, Kjeld Søballe, Jørgen Baas
The bone-implant interface of cementless orthopedic implants can be described as a series of uneven sized gaps with discontinuous areas of direct bone-implant contact. Bridging these voids and crevices by addition of an anabolic stimulus to increase new bone formation can potentially improve osseointegration of implants. Bone Morphogenetic Protein 2 (BMP-2) stimulates osteoblast formation to increase new bone formation but indirectly stimulates osteoclast activity. In this experiment we investigate the hypothesis that osseointegration, defined as mechanical push-out and histomorphometry, depends on the dose of BMP-2 when delivered as an anabolic agent with systemic administration of the anti-resorptive agent zoledronate to curb an increase in osteoclast activity...
October 4, 2017: Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society
https://www.readbyqxmd.com/read/28975737/bifunctional-platinum-ii-complexes-with-bisphosphonates-substituted-diamine-derivatives-synthesis-and-in-vitro-cytotoxicity
#18
Yanyan Sun, Jian Zhao, Zhongling Ji
A series of N,N'-dibisphosphonate-containing 1,3-propanediamine derivatives (L1-L6) and their corresponding dichloridoplatinum(II) complexes (1-6) have been synthesized and characterized by elemental analysis, (1) H NMR, (13) C NMR, (31) P NMR and HRMS spectra. The in vitro antitumor activities of compounds L1-L6 and 1-6 were tested by WST-8 assay with Cell Counting Kit-8, indicating that platinum-based complexes 1-6 showed higher cytotoxicity than corresponding ligands L1-L6 against A549 and MG-63, especially complex 2 which displayed comparable cytotoxicity to those of cisplatin and zoledronate after 48 h incubation...
October 4, 2017: Chemistry & Biodiversity
https://www.readbyqxmd.com/read/28973221/sclerostin-blockade-and-zoledronic-acid-improve-bone-mass-and-strength-in-male-mice-with-exogenous-hyperthyroidism
#19
Elena Tsourdi, Franziska Lademann, Michael S Ominsky, Eddy Rijntjes, Josef Köhrle, Barbara M Misof, Paul Roschger, Klaus Klaushofer, Lorenz C Hofbauer, Martina Rauner
Thyroid hormones affect several aspects of bone biology. Hyperthyroidism in mice is associated with low bone mass, high bone turnover, and high concentrations of sclerostin, a potent Wnt inhibitor. Here, we explored the effects of either increasing bone formation with sclerostin antibodies (Scl-Ab) or reducing bone turnover with bisphosphonates on bone mass and strength in hyperthyroid mice. Twelve-week-old C57BL/6 male mice were rendered hyperthyroid using T4 (1.2 µg/ml T4 added to the drinking water) and treated with 20 mg/kg Scl-Ab 2x/week or 100 µg/kg zoledronic acid (ZOL) 1x/week or PBS for 4 weeks...
July 11, 2017: Endocrinology
https://www.readbyqxmd.com/read/28962856/a-new-mathematical-approach-to-predict-the-actual-drug-release-from-hydrogels
#20
Amir Hossein Zeinali Kalkhoran, Omid Vahidi, Seyed Morteza Naghib
In the present study, we have developed a mathematical model of drug release from a film of highly swellable gelatin based hydrogel mixed with graphene. The model considers the hydrogel volume expansion because of the swelling as well as the non-linear concentration dependence of the diffusion coefficients for the solvent and the drug. An additionl term is considered for the drug diffusion coefficient enabling the model to predict the drug maximum release from the hydrogel. The model parameters are estimated by genetic algorithem and the model resutls are validated using data sets obtained from experiments on Zoledronic acid, the model drug, loaded hydrogel samples made from several weigth ratios of gelatin to graphene crosslinked with different amounts of glutaraldehyde...
September 27, 2017: European Journal of Pharmaceutical Sciences
keyword
keyword
113547
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"